{
    "info": {
        "nct_id": "NCT05320198",
        "official_title": "A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia",
        "inclusion_criteria": "Inclusion Criteria for Participants with MF and Anemia\n\nParticipants are eligible for the study if all of the following criteria apply:\n\n1. Age 18 years or older at the time of signing the informed consent form (ICF).\n2. For Phase 1b: DIPSS score of 3 to 4 (intermediate 2 risk) or ≥5 (high-risk) primary MF, post PV MF, and/or post ET MF, as confirmed in the most recent local bone marrow biopsy report, according to WHO 2016 criteria.63\n\n   For Phase 2: In addition to the criteria above, DIPSS score of ≥2 (intermediate 1 risk) may also be included.\n3. Washout of at least 28 days prior to Screening of the following treatments:\n\n   1. Androgens\n   2. Erythropoietin\n   3. Cladribine\n   4. Immunomodulators (lenalidomide, thalidomide)\n   5. Interferon alpha-2a\n   6. Luspatercept/sotatercept\n   7. Systemic corticosteroids are permitted for non-hematological conditions if stable or decreasing dose for ≥28 days prior to Screening and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening.\n\n   Screening can begin before the 28 day washout is completed, but the washout period must be completed prior to collection of Screening blood samples.\n4. Anemia:\n\n   For Phase 1b: Hgb <10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion, or Hgb <10 g/dL and receiving RBC transfusions periodically but not meeting criteria for TD participant as defined for the TD Cohort (see Section 6.3). The baseline Hgb value for these participants is the lowest Hgb level during the 84 days prior to Screening, or RBC transfusion dependence, defined as an RBC transfusion frequency of 6 units PRBC over the 84 days immediately prior to Screening There must not be any consecutive 42 day period without an RBC transfusion in the 84 day period, and the last transfusion must be within 28 days prior to Screening.\n\n   For Phase 2:\n\n   TD high transfusion burden cohort: RBC transfusion dependence, defined as an RBC transfusion requirement of 3 to 12 PRBC units over the 84 days immediately prior to Screening\n\n   TD low transfusion burden cohort: RBC transfusion dependence, defined as an RBC transfusion requirement of 1 to 2 PRBC units over the 84 days immediately prior to Screening\n\n   nTD cohort: Non-transfusion dependence, baseline Hgb <10 g/dL as defined on ≥3 assessments over 84 days prior to Screening, without RBC transfusion\n\n   Exploratory cohort: RBC TD or nTD with momelotinib or pacritinib (note: enrollment will commence with momelotinib only; pacritinib enrollment will be considered after initial safety and efficacy review)\n5. Stable dosing of MF-directed therapy:\n\n   1. Hydroxyurea, or, if taking any other treatment for MF, stable for at least 28 days prior to Screening.\n   2. JAK inhibitors require 12 weeks of stable dosing prior to Screening. For the TD cohort and nTD cohort, JAK inhibitors allowed include ruxolitinib and fedratinib. For the exploratory cohort, JAK inhibitors allowed include momelotinib and pacritinib (note: enrollment will commence with momelotinib only; pacritinib enrollment will be considered after initial safety and efficacy review).\n   3. If the participant discontinues JAK inhibitor (including momelotinib) and/or hydroxyurea prior to Screening, a 60-day washout period is required.\n6. Eastern Cooperative Oncology Group (ECOG) performance score ≤2.\n7. Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening.\n8. Transferrin saturation <75% (local lab acceptable)\n9. Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review. Required for TD high participants only.\n10. Serum ferritin ≥30 50 µg/L at Screening.\n11. Platelet count ≥25,000/µL and <1,000,000/µL; neutrophils ≥1,000/µL; and total white blood cell (WBC) count <50,000/µL at Screening.\n12. Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula.\n13. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3x upper limit of normal (ULN) at Screening.\n14. Direct bilirubin <2x ULN at Screening. Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis or Gilbert's syndrome, with approval from Sponsor.\n15. If male with female sexual partner(s) of childbearing potential, agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose:\n\n    1. Stable hormonal contraceptive (≥3 months; female partner) in conjunction with a barrier method (eg, condom or diaphragm [female partner])\n    2. Intrauterine device in place for at least 3 months (female partner)\n    3. Surgically sterile by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)\n    4. Confirmed successful vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)\n16. If female, then EITHER postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea and serum follicle-stimulating hormone (FSH) >40 mIU/mL at Screening, or at least 6 weeks following surgical menopause (bilateral oophorectomy or hysterectomy); OR agreeable to use highly effective contraception methods (listed below) on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug:\n\n    1. Stable hormonal contraceptive (≥3 months) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)\n    2. Intrauterine device in place for at least 3 months\n    3. Tubal ligation or single male partner with vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)\n17. Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2).\n18. Able to understand the study aims, procedures, and requirements, and provide written informed consent.\n19. Able to comply with all study procedures.\n\nInclusion Criteria for Exploratory Cohort of Participants with MDS and Anemia\n\nParticipants are eligible for the MDS exploratory cohort if all of the following criteria apply:\n\n1. Age 18 years or older at the time of signing the ICF.\n2. Molecular International Prognostic Scoring System (IPSS-R) classification of very low, low, or intermediate (ie, lower risk) MDS or MDS/MPN with ringed sideroblasts and thrombocytosis (RS-T) as confirmed in the most recent local bone marrow biopsy report according to WHO criteria.\n3. Washout of at least 28 days is required for prior anemia/neutropenia-directed therapies, including:\n\n   1. Androgens\n   2. Erythropoietin-stimulating agents\n   3. Luspatercept or sotatercept (ACE-011)\n   4. Imetelstat\n   5. Granulocyte colony-stimulating factor (GCSF) OR granulocyte-macrophage CSF (GM-CSF)\n   6. Systemic corticosteroids (except for participants on a stable or decreasing dose for ≥28 days prior to randomization for non-hematological conditions and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening) Screening can begin before the 28-day washout is completed, but the washout period must be completed prior to collection of Screening blood samples.\n4. Anemia:\n\n   1. Baseline Hgb of <10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion, or Hgb <10 g/dL and receiving RBC transfusions periodically during the 84 days prior to Screening\n   2. Medical history of ≤12 units of PRBC for MDS and anemia\n5. ECOG performance score ≤2\n6. Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening\n7. Transferrin saturation <75% (local lab acceptable)\n8. Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review\n9. Serum ferritin ≥50 μg/L at Screening\n10. Platelet count ≥25,000/μL and <1,000,000/μL, and total WBC count <50,000/μL at Screening or otherwise approved by Sponsor\n11. eGFR ≥30 mL/min/1.73 m2 by the CKD-EPI formula\n12. AST and ALT <3x ULN at Screening\n13. Direct bilirubin <2x ULN at Screening. Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis.\n14. If male with female sexual partner(s) of childbearing potential, agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose:\n\n    1. Stable hormonal contraceptive (≥3 months; female partner) in conjunction with a barrier method (eg, condom or diaphragm [female partner])\n    2. Intrauterine device in place for at least 3 months (female partner)\n    3. Surgically sterile hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)\n    4. Confirmed successful vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)\n15. If female, then EITHER postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea and serum FSH >40 mIU/mL at Screening, or at least 6 weeks following surgical menopause (bilateral oophorectomy or hysterectomy); OR agreeable to use one of the following highly effective contraception methods on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug:\n\n    1. Stable hormonal contraceptive (≥3 months) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)\n    2. Intrauterine device in place for at least 3 months\n    3. Tubal ligation or single male partner with vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)\n16. Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2).\n17. Able to understand the study aims, procedures, and requirements, and provide written informed consent.\n18. Able to comply with all study procedures.\n\nExclusion Criteria Exclusion Criteria for Participants with MF and Anemia\n\nParticipants are excluded from the study if any of the following criteria apply:\n\nMedical History, Participants with MF and Anemia\n\n1. Hereditary hemochromatosis\n2. Hemoglobinopathy or intrinsic RBC defect associated with anemia\n3. Total splenectomy\n4. Hematopoietic cell transplant within the past 2 years or graft vs host disease requiring immunosuppression\n5. Current anemia from iron deficiency, vitamin B12 or folate deficiency, infection, or bleeding\n6. Active immune-mediated hemolytic anemia\n7. Symptomatic bleeding, unrelated to surgery, in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥2 g/dL or leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening\n8. Major surgery within 8 weeks prior to Screening or incomplete recovery from any previous surgery\n9. Malignancy with the past 3 years, other than primary MF, post ET MF, or post PV MF. The following history or concurrent conditions are allowed:\n\n   1. Basal or squamous cell carcinoma\n   2. Carcinoma in situ of the cervix or the breast\n   3. Histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system) A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement\n10. Stroke, deep vein thrombosis, or pulmonary or arterial embolism within 3 months prior to Screening\n11. Known allergic reaction to any study drug excipient, or anaphylaxis to any food or drug\n12. A history of anti-drug antibody formation\n13. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ventricular ejection fraction <35%\n14. Hepatitis B or C, or human immunodeficiency virus (HIV) with detectable viral load\n15. Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment) Treatment History, Medical History, Participants with MF and Anemia\n16. Iron chelation therapy in the 28 days prior to Screening\n17. Change in anticoagulant therapy regimen within 8 weeks prior to Screening Laboratory Exclusions, Medical History, Participants with MF and Anemia\n18. Peripheral blood myeloblasts ≥10% of WBC differential at most recent evaluation prior to Screening\n19. Positive direct antiglobulin test in conjunction with a reactive RBC eluate at Screening Miscellaneous, Medical History, Participants with MF and Anemia\n20. Pregnant or lactating\n21. Condition or concomitant medication that would confound the ability to interpret study data\n22. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study\n23. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days prior to Screening\n\nExclusion Criteria for Exploratory Cohort of Participants with MDS and Anemia\n\nParticipants are excluded from the MDS exploratory cohort if any of the following criteria apply:\n\nMedical History, Participants with MDS and Anemia\n\n1. Secondary MDS, ie, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation from other diseases\n2. Peripheral blasts ≥5%\n3. Prior treatment with hypomethylating agent or other acute myeloid leukemia (AML)-like combination chemotherapy\n4. Prior treatment with >1anemia-directed therapies including:\n\n   * Luspatercept or sotatercept (ACE-011)\n   * Erythropoietin-stimulating agent\n   * Imetelstat\n5. Hereditary hemochromatosis\n6. Hemoglobinopathy or intrinsic RBC defect associated with anemia\n7. Total splenectomy\n8. Hematopoietic cell transplant within the past 10 years\n9. Current anemia from iron deficiency, vitamin B12 or folate deficiency, infection, or bleeding\n10. Active immune-mediated hemolytic anemia\n11. Symptomatic bleeding, unrelated to surgery, in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥2 g/dL or leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening\n12. Major surgery within 8 weeks prior to Screening or incomplete recovery from any previous surgery\n13. Malignancy within the past 3 years, other than MDS or MDS/MPN without excess blasts. The following history or concurrent conditions are allowed:\n\n    1. basal or squamous cell carcinoma\n    2. carcinoma in situ of the cervix or the breast\n    3. histologic finding of prostate cancer (T1a or T1b using the TNM clinical staging system) A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement\n14. Stroke, deep vein thrombosis, or pulmonary or arterial embolism within 6 months prior to Screening\n15. Known allergic reaction to any study drug excipient, or anaphylaxis to any food or drug\n16. A history of antidrug antibody formation\n17. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ventricular ejection fraction <35%\n18. Active hepatitis B or C, or HIV with detectable viral load\n19. Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment) Treatment History, Participants with MDS and Anemia\n20. Iron chelation therapy in the 28 days prior to Screening\n21. Change in anticoagulant therapy regimen within 8 weeks prior to Screening Laboratory Exclusions, Participants with MDS and Anemia\n22. Positive direct antiglobulin test in conjunction with a reactive RBC eluate at Screening Miscellaneous, Participants with MDS and Anemia\n23. Pregnant or lactating\n24. Condition or concomitant medication that would confound the ability to interpret study data\n25. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study\n26. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days prior to Screening\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "13. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ventricular ejection fraction <35%",
            "criterions": [
                {
                    "exact_snippets": "Inadequately controlled heart disease (New York Heart Association Classification 3 or 4)",
                    "criterion": "heart disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "inadequately controlled"
                        },
                        {
                            "requirement_type": "NYHA classification",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "known to have left ventricular ejection fraction <35%",
                    "criterion": "left ventricular ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 35,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Stable hormonal contraceptive (≥3 months) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
            "criterions": [
                {
                    "exact_snippets": "Stable hormonal contraceptive (≥3 months)",
                    "criterion": "hormonal contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                    "criterion": "barrier contraceptive method use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "19. Able to comply with all study procedures.",
            "criterions": [
                {
                    "exact_snippets": "Able to comply with all study procedures.",
                    "criterion": "compliance with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Able to understand the study aims, procedures, and requirements, and provide written informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Able to understand the study aims, procedures, and requirements",
                    "criterion": "understanding of study aims, procedures, and requirements",
                    "requirements": [
                        {
                            "requirement_type": "cognitive ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "provide written informed consent",
                    "criterion": "written informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Anemia:",
            "criterions": [
                {
                    "exact_snippets": "Anemia:",
                    "criterion": "anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. ECOG performance score ≤2",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance score ≤2",
                    "criterion": "ECOG performance score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. eGFR ≥30 mL/min/1.73 m2 by the CKD-EPI formula",
            "criterions": [
                {
                    "exact_snippets": "eGFR ≥30 mL/min/1.73 m2 by the CKD-EPI formula",
                    "criterion": "eGFR (estimated glomerular filtration rate)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min/1.73 m2"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "CKD-EPI formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Inclusion Criteria for Exploratory Cohort of Participants with MDS and Anemia",
            "criterions": [
                {
                    "exact_snippets": "Participants with MDS",
                    "criterion": "myelodysplastic syndromes (MDS)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Anemia",
                    "criterion": "anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Able to comply with all study procedures.",
            "criterions": [
                {
                    "exact_snippets": "Able to comply with all study procedures.",
                    "criterion": "compliance with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Intrauterine device in place for at least 3 months",
            "criterions": [
                {
                    "exact_snippets": "Intrauterine device in place",
                    "criterion": "intrauterine device",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for at least 3 months",
                    "criterion": "intrauterine device duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. If the participant discontinues JAK inhibitor (including momelotinib) and/or hydroxyurea prior to Screening, a 60-day washout period is required.",
            "criterions": [
                {
                    "exact_snippets": "participant discontinues JAK inhibitor (including momelotinib) and/or hydroxyurea prior to Screening, a 60-day washout period is required",
                    "criterion": "prior use of JAK inhibitor or hydroxyurea",
                    "requirements": [
                        {
                            "requirement_type": "discontinuation prior to screening",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Surgically sterile hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
            "criterions": [
                {
                    "exact_snippets": "Surgically sterile hysterectomy",
                    "criterion": "hysterectomy",
                    "requirements": [
                        {
                            "requirement_type": "surgical sterility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bilateral oophorectomy",
                    "criterion": "bilateral oophorectomy",
                    "requirements": [
                        {
                            "requirement_type": "surgical sterility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bilateral tubal ligation",
                    "criterion": "bilateral tubal ligation",
                    "requirements": [
                        {
                            "requirement_type": "surgical sterility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                    "criterion": "barrier method contraception",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Serum ferritin ≥50 μg/L at Screening",
            "criterions": [
                {
                    "exact_snippets": "Serum ferritin ≥50 μg/L at Screening",
                    "criterion": "serum ferritin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "μg/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Carcinoma in situ of the cervix or the breast",
            "criterions": [
                {
                    "exact_snippets": "Carcinoma in situ of the cervix",
                    "criterion": "carcinoma in situ of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Carcinoma in situ of the ... breast",
                    "criterion": "carcinoma in situ of the breast",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Washout of at least 28 days prior to Screening of the following treatments:",
            "criterions": [
                {
                    "exact_snippets": "Washout of at least 28 days prior to Screening",
                    "criterion": "washout period",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to Screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Participants are excluded from the study if any of the following criteria apply:",
            "criterions": [
                {
                    "exact_snippets": "Participants are excluded from the study if any of the following criteria apply:",
                    "criterion": "exclusion criteria statement",
                    "requirements": [
                        {
                            "requirement_type": "statement",
                            "expected_value": "This is an introductory statement indicating that specific exclusion criteria will follow; no atomic patient property is tested in this line."
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Current anemia from iron deficiency, vitamin B12 or folate deficiency, infection, or bleeding",
            "criterions": [
                {
                    "exact_snippets": "Current anemia from iron deficiency",
                    "criterion": "anemia due to iron deficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current anemia from ... vitamin B12 ... deficiency",
                    "criterion": "anemia due to vitamin B12 deficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current anemia from ... folate deficiency",
                    "criterion": "anemia due to folate deficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current anemia from ... infection",
                    "criterion": "anemia due to infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current anemia from ... bleeding",
                    "criterion": "anemia due to bleeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening",
            "criterions": [
                {
                    "exact_snippets": "Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening",
                    "criterion": "infusion of hematopoietic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "anticipated timing",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "months after Screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Able to understand the study aims, procedures, and requirements, and provide written informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Able to understand the study aims, procedures, and requirements",
                    "criterion": "understanding of study aims, procedures, and requirements",
                    "requirements": [
                        {
                            "requirement_type": "cognitive ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "provide written informed consent",
                    "criterion": "written informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Baseline Hgb of <10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion, or Hgb <10 g/dL and receiving RBC transfusions periodically during the 84 days prior to Screening",
            "criterions": [
                {
                    "exact_snippets": "Baseline Hgb of <10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion",
                    "criterion": "hemoglobin (Hgb) level",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        },
                        {
                            "requirement_type": "number of assessments",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "assessments"
                            }
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "84 days prior to Screening"
                        },
                        {
                            "requirement_type": "RBC transfusion",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Hgb <10 g/dL and receiving RBC transfusions periodically during the 84 days prior to Screening",
                    "criterion": "hemoglobin (Hgb) level and RBC transfusion",
                    "requirements": [
                        {
                            "requirement_type": "Hgb value",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        },
                        {
                            "requirement_type": "RBC transfusion",
                            "expected_value": "periodically during the 84 days prior to Screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Luspatercept/sotatercept",
            "criterions": [
                {
                    "exact_snippets": "Luspatercept/sotatercept",
                    "criterion": "Luspatercept or sotatercept use",
                    "requirements": [
                        {
                            "requirement_type": "use or exposure",
                            "expected_value": "Luspatercept or sotatercept"
                        }
                    ]
                }
            ]
        },
        {
            "line": "For Phase 1b: Hgb <10 g/dL on ≥3 assessments over 84 days prior to Screening, without RBC transfusion, or Hgb <10 g/dL and receiving RBC transfusions periodically but not meeting criteria for TD participant as defined for the TD Cohort (see Section 6.3). The baseline Hgb value for these participants is the lowest Hgb level during the 84 days prior to Screening, or RBC transfusion dependence, defined as an RBC transfusion frequency of 6 units PRBC over the 84 days immediately prior to Screening There must not be any consecutive 42 day period without an RBC transfusion in the 84 day period, and the last transfusion must be within 28 days prior to Screening.",
            "criterions": [
                {
                    "exact_snippets": "Hgb <10 g/dL on ≥3 assessments over 84 days prior to Screening",
                    "criterion": "hemoglobin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        },
                        {
                            "requirement_type": "number of assessments",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "assessments"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "84 days prior to Screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "without RBC transfusion",
                    "criterion": "RBC transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hgb <10 g/dL and receiving RBC transfusions periodically but not meeting criteria for TD participant as defined for the TD Cohort",
                    "criterion": "hemoglobin level and RBC transfusion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        },
                        {
                            "requirement_type": "RBC transfusion periodicity",
                            "expected_value": "periodically"
                        },
                        {
                            "requirement_type": "TD participant status",
                            "expected_value": "not meeting criteria for TD participant"
                        }
                    ]
                },
                {
                    "exact_snippets": "The baseline Hgb value for these participants is the lowest Hgb level during the 84 days prior to Screening",
                    "criterion": "baseline hemoglobin value",
                    "requirements": [
                        {
                            "requirement_type": "lowest value",
                            "expected_value": "during the 84 days prior to Screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "RBC transfusion dependence, defined as an RBC transfusion frequency of 6 units PRBC over the 84 days immediately prior to Screening",
                    "criterion": "RBC transfusion dependence",
                    "requirements": [
                        {
                            "requirement_type": "RBC transfusion frequency",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "units PRBC"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "84 days immediately prior to Screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "There must not be any consecutive 42 day period without an RBC transfusion in the 84 day period",
                    "criterion": "RBC transfusion interval",
                    "requirements": [
                        {
                            "requirement_type": "maximum interval without transfusion",
                            "expected_value": {
                                "operator": "<=",
                                "value": 42,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "84 day period"
                        }
                    ]
                },
                {
                    "exact_snippets": "the last transfusion must be within 28 days prior to Screening",
                    "criterion": "timing of last RBC transfusion",
                    "requirements": [
                        {
                            "requirement_type": "time since last transfusion",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to Screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Inclusion Criteria for Participants with MF and Anemia",
            "criterions": [
                {
                    "exact_snippets": "MF",
                    "criterion": "myelofibrosis (MF)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Anemia",
                    "criterion": "anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Hereditary hemochromatosis",
            "criterions": [
                {
                    "exact_snippets": "Hereditary hemochromatosis",
                    "criterion": "hereditary hemochromatosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Cladribine",
            "criterions": [
                {
                    "exact_snippets": "Cladribine",
                    "criterion": "cladribine",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Known allergic reaction to any study drug excipient, or anaphylaxis to any food or drug",
            "criterions": [
                {
                    "exact_snippets": "Known allergic reaction to any study drug excipient",
                    "criterion": "allergic reaction to study drug excipient",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "anaphylaxis to any food or drug",
                    "criterion": "anaphylaxis to food or drug",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Medical History, Participants with MF and Anemia",
            "criterions": [
                {
                    "exact_snippets": "Participants with MF",
                    "criterion": "myelofibrosis (MF)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with ... Anemia",
                    "criterion": "anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Hematopoietic cell transplant within the past 2 years or graft vs host disease requiring immunosuppression",
            "criterions": [
                {
                    "exact_snippets": "Hematopoietic cell transplant within the past 2 years",
                    "criterion": "hematopoietic cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "graft vs host disease requiring immunosuppression",
                    "criterion": "graft vs host disease",
                    "requirements": [
                        {
                            "requirement_type": "immunosuppression requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Exploratory cohort: RBC TD or nTD with momelotinib or pacritinib (note: enrollment will commence with momelotinib only; pacritinib enrollment will be considered after initial safety and efficacy review)",
            "criterions": [
                {
                    "exact_snippets": "RBC TD or nTD",
                    "criterion": "red blood cell transfusion dependence status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "transfusion dependent",
                                "non-transfusion dependent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "with momelotinib or pacritinib (note: enrollment will commence with momelotinib only; pacritinib enrollment will be considered after initial safety and efficacy review)",
                    "criterion": "treatment received",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": [
                                "momelotinib",
                                "pacritinib"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Immunomodulators (lenalidomide, thalidomide)",
            "criterions": [
                {
                    "exact_snippets": "Immunomodulators (lenalidomide, thalidomide)",
                    "criterion": "immunomodulator use",
                    "requirements": [
                        {
                            "requirement_type": "use or exposure",
                            "expected_value": [
                                "lenalidomide",
                                "thalidomide"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Malignancy with the past 3 years, other than primary MF, post ET MF, or post PV MF. The following history or concurrent conditions are allowed:",
            "criterions": [
                {
                    "exact_snippets": "Malignancy with the past 3 years, other than primary MF, post ET MF, or post PV MF.",
                    "criterion": "malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history within time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "primary MF",
                                "post ET MF",
                                "post PV MF"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Stable hormonal contraceptive (≥3 months) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
            "criterions": [
                {
                    "exact_snippets": "Stable hormonal contraceptive (≥3 months)",
                    "criterion": "hormonal contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                    "criterion": "barrier contraceptive method use",
                    "requirements": [
                        {
                            "requirement_type": "concurrent_use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Tubal ligation or single male partner with vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
            "criterions": [
                {
                    "exact_snippets": "Tubal ligation",
                    "criterion": "tubal ligation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "single male partner with vasectomy",
                    "criterion": "male partner vasectomy",
                    "requirements": [
                        {
                            "requirement_type": "partner vasectomy status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                    "criterion": "barrier method contraception",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method type",
                            "expected_value": [
                                "condom (male)",
                                "condom (female)",
                                "diaphragm"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Active immune-mediated hemolytic anemia",
            "criterions": [
                {
                    "exact_snippets": "Active immune-mediated hemolytic anemia",
                    "criterion": "immune-mediated hemolytic anemia",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Platelet count ≥25,000/µL and <1,000,000/µL; neutrophils ≥1,000/µL; and total white blood cell (WBC) count <50,000/µL at Screening.",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥25,000/µL and <1,000,000/µL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 25000,
                                        "unit": "/µL"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 1000000,
                                        "unit": "/µL"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "neutrophils ≥1,000/µL",
                    "criterion": "neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "/µL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "total white blood cell (WBC) count <50,000/µL",
                    "criterion": "total white blood cell (WBC) count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50000,
                                "unit": "/µL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment) Treatment History, Medical History, Participants with MF and Anemia",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)",
                    "criterion": "infection status",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "fungal",
                                "bacterial",
                                "viral"
                            ]
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "symptoms",
                            "expected_value": "ongoing signs/symptoms related to the infection"
                        },
                        {
                            "requirement_type": "response to treatment",
                            "expected_value": "without improvement despite appropriate treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment History",
                    "criterion": "treatment history",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Medical History",
                    "criterion": "medical history",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with MF and Anemia",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "disease",
                            "expected_value": "myelofibrosis (MF)"
                        },
                        {
                            "requirement_type": "comorbidity",
                            "expected_value": "anemia"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Tubal ligation or single male partner with vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
            "criterions": [
                {
                    "exact_snippets": "Tubal ligation",
                    "criterion": "tubal ligation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "single male partner with vasectomy",
                    "criterion": "male partner vasectomy",
                    "requirements": [
                        {
                            "requirement_type": "partner vasectomy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                    "criterion": "barrier method contraception",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method type",
                            "expected_value": [
                                "condom (male)",
                                "condom (female)",
                                "diaphragm"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. AST and ALT <3x ULN at Screening",
            "criterions": [
                {
                    "exact_snippets": "AST ... <3x ULN at Screening",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT <3x ULN at Screening",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Stable hormonal contraceptive (≥3 months; female partner) in conjunction with a barrier method (eg, condom or diaphragm [female partner])",
            "criterions": [
                {
                    "exact_snippets": "Stable hormonal contraceptive (≥3 months; female partner)",
                    "criterion": "hormonal contraceptive use (female partner)",
                    "requirements": [
                        {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in conjunction with a barrier method (eg, condom or diaphragm [female partner])",
                    "criterion": "barrier contraceptive method (female partner)",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Major surgery within 8 weeks prior to Screening or incomplete recovery from any previous surgery",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 8 weeks prior to Screening",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "timing relative to screening",
                            "expected_value": "prior to Screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "incomplete recovery from any previous surgery",
                    "criterion": "recovery from previous surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula.",
            "criterions": [
                {
                    "exact_snippets": "Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula.",
                    "criterion": "estimated glomerular filtration rate (eGFR)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min/1.73 m2"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "For Phase 2: In addition to the criteria above, DIPSS score of ≥2 (intermediate 1 risk) may also be included.",
            "criterions": [
                {
                    "exact_snippets": "DIPSS score of ≥2 (intermediate 1 risk)",
                    "criterion": "DIPSS score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Hemoglobinopathy or intrinsic RBC defect associated with anemia",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobinopathy",
                    "criterion": "hemoglobinopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intrinsic RBC defect associated with anemia",
                    "criterion": "intrinsic RBC defect associated with anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening.",
            "criterions": [
                {
                    "exact_snippets": "Infusion of hematopoietic stem cell transplant not anticipated within 8 months after Screening.",
                    "criterion": "hematopoietic stem cell transplant infusion",
                    "requirements": [
                        {
                            "requirement_type": "anticipated_timing",
                            "expected_value": {
                                "operator": ">",
                                "value": 8,
                                "unit": "months after Screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Stable hormonal contraceptive (≥3 months; female partner) in conjunction with a barrier method (eg, condom or diaphragm [female partner])",
            "criterions": [
                {
                    "exact_snippets": "Stable hormonal contraceptive (≥3 months; female partner)",
                    "criterion": "hormonal contraceptive use (female partner)",
                    "requirements": [
                        {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in conjunction with a barrier method (eg, condom or diaphragm [female partner])",
                    "criterion": "barrier contraceptive method (female partner)",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Symptomatic bleeding, unrelated to surgery, in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥2 g/dL or leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic bleeding, unrelated to surgery, in a critical area or organ",
                    "criterion": "symptomatic bleeding",
                    "requirements": [
                        {
                            "requirement_type": "relation to surgery",
                            "expected_value": "unrelated"
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "critical area or organ"
                        }
                    ]
                },
                {
                    "exact_snippets": "bleeding causing a decrease in Hgb of ≥2 g/dL",
                    "criterion": "bleeding-induced hemoglobin decrease",
                    "requirements": [
                        {
                            "requirement_type": "hemoglobin decrease",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "bleeding ... leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening",
                    "criterion": "bleeding-induced RBC transfusion",
                    "requirements": [
                        {
                            "requirement_type": "RBC transfusion units",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "units"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "6 months prior to Screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2).",
            "criterions": [
                {
                    "exact_snippets": "Negative urine pregnancy test (females of childbearing potential)",
                    "criterion": "urine pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "females of childbearing potential",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at Screening (Days 28 to 2)",
                    "criterion": "timing of test",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system) A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement",
            "criterions": [
                {
                    "exact_snippets": "Histologic finding of prostate cancer",
                    "criterion": "prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "histologic finding",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system",
                    "criterion": "prostate cancer TNM stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "T1a",
                                "T1b"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement",
                    "criterion": "history of completed treatment of stage 1-2 cancers",
                    "requirements": [
                        {
                            "requirement_type": "history of completed treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "nTD cohort: Non-transfusion dependence, baseline Hgb <10 g/dL as defined on ≥3 assessments over 84 days prior to Screening, without RBC transfusion",
            "criterions": [
                {
                    "exact_snippets": "Non-transfusion dependence",
                    "criterion": "transfusion dependence",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "baseline Hgb <10 g/dL",
                    "criterion": "hemoglobin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "as defined on ≥3 assessments over 84 days prior to Screening",
                    "criterion": "hemoglobin assessments",
                    "requirements": [
                        {
                            "requirement_type": "number of assessments",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "assessments"
                            }
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "84 days prior to Screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "without RBC transfusion",
                    "criterion": "RBC transfusion",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Androgens",
            "criterions": [
                {
                    "exact_snippets": "Androgens",
                    "criterion": "androgens",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. If female, then EITHER postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea and serum FSH >40 mIU/mL at Screening, or at least 6 weeks following surgical menopause (bilateral oophorectomy or hysterectomy); OR agreeable to use one of the following highly effective contraception methods on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug:",
            "criterions": [
                {
                    "exact_snippets": "If female",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "postmenopausal",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "amenorrhea duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "amenorrhea type",
                            "expected_value": [
                                "natural",
                                "spontaneous"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "serum FSH >40 mIU/mL at Screening",
                    "criterion": "serum FSH level",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "mIU/mL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 6 weeks following surgical menopause (bilateral oophorectomy or hysterectomy)",
                    "criterion": "time since surgical menopause",
                    "requirements": [
                        {
                            "requirement_type": "duration since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "surgical menopause type",
                            "expected_value": [
                                "bilateral oophorectomy",
                                "hysterectomy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "agreeable to use one of the following highly effective contraception methods on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "contraception start time",
                            "expected_value": "on Day 1 or earlier"
                        },
                        {
                            "requirement_type": "contraception duration after last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. If female, then EITHER postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea and serum follicle-stimulating hormone (FSH) >40 mIU/mL at Screening, or at least 6 weeks following surgical menopause (bilateral oophorectomy or hysterectomy); OR agreeable to use highly effective contraception methods (listed below) on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug:",
            "criterions": [
                {
                    "exact_snippets": "If female",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "postmenopausal, defined as at least 12 months of natural, spontaneous amenorrhea",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "postmenopausal"
                        },
                        {
                            "requirement_type": "duration of amenorrhea",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "serum follicle-stimulating hormone (FSH) >40 mIU/mL at Screening",
                    "criterion": "serum follicle-stimulating hormone (FSH) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "mIU/mL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 6 weeks following surgical menopause (bilateral oophorectomy or hysterectomy)",
                    "criterion": "time since surgical menopause",
                    "requirements": [
                        {
                            "requirement_type": "duration since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "agreeable to use highly effective contraception methods ... on Day 1 (or earlier) for at least 8 weeks after the last dose of study drug",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of contraception use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Luspatercept or sotatercept (ACE-011)",
            "criterions": [
                {
                    "exact_snippets": "Luspatercept or sotatercept (ACE-011)",
                    "criterion": "prior treatment with luspatercept or sotatercept (ACE-011)",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Intrauterine device in place for at least 3 months",
            "criterions": [
                {
                    "exact_snippets": "Intrauterine device in place",
                    "criterion": "intrauterine device",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for at least 3 months",
                    "criterion": "intrauterine device duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Granulocyte colony-stimulating factor (GCSF) OR granulocyte-macrophage CSF (GM-CSF)",
            "criterions": [
                {
                    "exact_snippets": "Granulocyte colony-stimulating factor (GCSF) OR granulocyte-macrophage CSF (GM-CSF)",
                    "criterion": "colony-stimulating factor administration",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "GCSF",
                                "GM-CSF"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review",
            "criterions": [
                {
                    "exact_snippets": "Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review",
                    "criterion": "liver iron concentration by MRI",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 7,
                                "unit": "mg/g dry weight"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 3 months of eligibility confirmation by central review"
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Active immune-mediated hemolytic anemia",
            "criterions": [
                {
                    "exact_snippets": "Active immune-mediated hemolytic anemia",
                    "criterion": "immune-mediated hemolytic anemia",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Screening can begin before the 28 day washout is completed, but the washout period must be completed prior to collection of Screening blood samples.",
            "criterions": [
                {
                    "exact_snippets": "the washout period must be completed prior to collection of Screening blood samples",
                    "criterion": "washout period",
                    "requirements": [
                        {
                            "requirement_type": "completion timing",
                            "expected_value": "must be completed prior to collection of Screening blood samples"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Age 18 years or older at the time of signing the informed consent form (ICF).",
            "criterions": [
                {
                    "exact_snippets": "Age 18 years or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Luspatercept or sotatercept (ACE-011)",
            "criterions": [
                {
                    "exact_snippets": "Luspatercept or sotatercept (ACE-011)",
                    "criterion": "luspatercept or sotatercept (ACE-011) administration",
                    "requirements": [
                        {
                            "requirement_type": "administration",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Intrauterine device in place for at least 3 months (female partner)",
            "criterions": [
                {
                    "exact_snippets": "Intrauterine device in place",
                    "criterion": "intrauterine device",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for at least 3 months",
                    "criterion": "intrauterine device duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "(female partner)",
                    "criterion": "female partner",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Eastern Cooperative Oncology Group (ECOG) performance score ≤2.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance score ≤2",
                    "criterion": "ECOG performance score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Surgically sterile by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner) in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
            "criterions": [
                {
                    "exact_snippets": "Surgically sterile by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner)",
                    "criterion": "female partner surgical sterility",
                    "requirements": [
                        {
                            "requirement_type": "sterility_method",
                            "expected_value": [
                                "hysterectomy",
                                "bilateral oophorectomy",
                                "bilateral tubal ligation"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                    "criterion": "barrier method contraception",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method_type",
                            "expected_value": [
                                "condom (male)",
                                "condom (female)",
                                "diaphragm"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. If male with female sexual partner(s) of childbearing potential, agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose:",
            "criterions": [
                {
                    "exact_snippets": "male with female sexual partner(s) of childbearing potential",
                    "criterion": "sexual partner's childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "partner_gender",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "partner_childbearing_potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement_to_use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 8,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Current anemia from iron deficiency, vitamin B12 or folate deficiency, infection, or bleeding",
            "criterions": [
                {
                    "exact_snippets": "Current anemia from iron deficiency",
                    "criterion": "anemia due to iron deficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current anemia from ... vitamin B12 ... deficiency",
                    "criterion": "anemia due to vitamin B12 deficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current anemia from ... folate deficiency",
                    "criterion": "anemia due to folate deficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current anemia from ... infection",
                    "criterion": "anemia due to infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current anemia from ... bleeding",
                    "criterion": "anemia due to bleeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Total splenectomy",
            "criterions": [
                {
                    "exact_snippets": "Total splenectomy",
                    "criterion": "splenectomy",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "total"
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Direct bilirubin <2x ULN at Screening. Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis.",
            "criterions": [
                {
                    "exact_snippets": "Direct bilirubin <2x ULN at Screening",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "Screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": ">=2x ULN"
                        },
                        {
                            "requirement_type": "attribution",
                            "expected_value": "ineffective erythropoiesis (as determined by Investigator)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Confirmed successful vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
            "criterions": [
                {
                    "exact_snippets": "Confirmed successful vasectomy",
                    "criterion": "vasectomy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "confirmed successful"
                        }
                    ]
                },
                {
                    "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                    "criterion": "barrier method contraception",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Exclusion Criteria for Exploratory Cohort of Participants with MDS and Anemia",
            "criterions": [
                {
                    "exact_snippets": "MDS",
                    "criterion": "myelodysplastic syndromes (MDS)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Anemia",
                    "criterion": "anemia",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "22. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study",
            "criterions": [
                {
                    "exact_snippets": "Other medical or psychiatric condition ... that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study",
                    "criterion": "other medical or psychiatric condition",
                    "requirements": [
                        {
                            "requirement_type": "risk assessment",
                            "expected_value": "would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study, in the judgment of the Investigator or Sponsor"
                        }
                    ]
                },
                {
                    "exact_snippets": "laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study",
                    "criterion": "laboratory finding (not specifically noted above)",
                    "requirements": [
                        {
                            "requirement_type": "risk assessment",
                            "expected_value": "would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study, in the judgment of the Investigator or Sponsor"
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Peripheral blood myeloblasts ≥10% of WBC differential at most recent evaluation prior to Screening",
            "criterions": [
                {
                    "exact_snippets": "Peripheral blood myeloblasts ≥10% of WBC differential at most recent evaluation prior to Screening",
                    "criterion": "peripheral blood myeloblasts",
                    "requirements": [
                        {
                            "requirement_type": "percentage of WBC differential",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. A history of antidrug antibody formation",
            "criterions": [
                {
                    "exact_snippets": "A history of antidrug antibody formation",
                    "criterion": "antidrug antibody formation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Basal or squamous cell carcinoma",
            "criterions": [
                {
                    "exact_snippets": "Basal or squamous cell carcinoma",
                    "criterion": "carcinoma type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "basal cell carcinoma",
                                "squamous cell carcinoma"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Iron chelation therapy in the 28 days prior to Screening",
            "criterions": [
                {
                    "exact_snippets": "Iron chelation therapy in the 28 days prior to Screening",
                    "criterion": "iron chelation therapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to Screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Participants are excluded from the MDS exploratory cohort if any of the following criteria apply:",
            "criterions": [
                {
                    "exact_snippets": "Participants are excluded from the MDS exploratory cohort",
                    "criterion": "MDS exploratory cohort participation",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Hemoglobinopathy or intrinsic RBC defect associated with anemia",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobinopathy",
                    "criterion": "hemoglobinopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intrinsic RBC defect associated with anemia",
                    "criterion": "intrinsic RBC defect associated with anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Anemia:",
            "criterions": [
                {
                    "exact_snippets": "Anemia:",
                    "criterion": "anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Interferon alpha-2a",
            "criterions": [
                {
                    "exact_snippets": "Interferon alpha-2a",
                    "criterion": "Interferon alpha-2a",
                    "requirements": [
                        {
                            "requirement_type": "exposure or use",
                            "expected_value": "Interferon alpha-2a"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Stable dosing of MF-directed therapy:",
            "criterions": [
                {
                    "exact_snippets": "Stable dosing of MF-directed therapy",
                    "criterion": "MF-directed therapy dosing",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "20. Pregnant or lactating",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Transferrin saturation <75% (local lab acceptable)",
            "criterions": [
                {
                    "exact_snippets": "Transferrin saturation <75% (local lab acceptable)",
                    "criterion": "transferrin saturation",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 75,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. carcinoma in situ of the cervix or the breast",
            "criterions": [
                {
                    "exact_snippets": "carcinoma in situ of the cervix",
                    "criterion": "carcinoma in situ of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinoma in situ of the ... breast",
                    "criterion": "carcinoma in situ of the breast",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "21. Condition or concomitant medication that would confound the ability to interpret study data",
            "criterions": [
                {
                    "exact_snippets": "Condition ... that would confound the ability to interpret study data",
                    "criterion": "condition",
                    "requirements": [
                        {
                            "requirement_type": "potential to confound study data interpretation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "concomitant medication that would confound the ability to interpret study data",
                    "criterion": "concomitant medication",
                    "requirements": [
                        {
                            "requirement_type": "potential to confound study data interpretation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Transferrin saturation <75% (local lab acceptable)",
            "criterions": [
                {
                    "exact_snippets": "Transferrin saturation <75% (local lab acceptable)",
                    "criterion": "transferrin saturation",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 75,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Confirmed successful vasectomy in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
            "criterions": [
                {
                    "exact_snippets": "Confirmed successful vasectomy",
                    "criterion": "vasectomy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "confirmed successful"
                        }
                    ]
                },
                {
                    "exact_snippets": "in conjunction with a barrier method (eg, condom [male or female] or diaphragm)",
                    "criterion": "barrier method contraception",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Hematopoietic cell transplant within the past 10 years",
            "criterions": [
                {
                    "exact_snippets": "Hematopoietic cell transplant within the past 10 years",
                    "criterion": "hematopoietic cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Stroke, deep vein thrombosis, or pulmonary or arterial embolism within 3 months prior to Screening",
            "criterions": [
                {
                    "exact_snippets": "Stroke ... within 3 months prior to Screening",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to Screening"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "deep vein thrombosis ... within 3 months prior to Screening",
                    "criterion": "deep vein thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to Screening"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "pulmonary or arterial embolism within 3 months prior to Screening",
                    "criterion": "pulmonary embolism",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to Screening"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "pulmonary or arterial embolism within 3 months prior to Screening",
                    "criterion": "arterial embolism",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to Screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Known allergic reaction to any study drug excipient, or anaphylaxis to any food or drug",
            "criterions": [
                {
                    "exact_snippets": "Known allergic reaction to any study drug excipient",
                    "criterion": "allergic reaction to study drug excipient",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "anaphylaxis to any food or drug",
                    "criterion": "anaphylaxis to food or drug",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Molecular International Prognostic Scoring System (IPSS-R) classification of very low, low, or intermediate (ie, lower risk) MDS or MDS/MPN with ringed sideroblasts and thrombocytosis (RS-T) as confirmed in the most recent local bone marrow biopsy report according to WHO criteria.",
            "criterions": [
                {
                    "exact_snippets": "Molecular International Prognostic Scoring System (IPSS-R) classification of very low, low, or intermediate (ie, lower risk) MDS",
                    "criterion": "IPSS-R classification",
                    "requirements": [
                        {
                            "requirement_type": "category",
                            "expected_value": [
                                "very low",
                                "low",
                                "intermediate"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "MDS or MDS/MPN with ringed sideroblasts and thrombocytosis (RS-T)",
                    "criterion": "disease diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "MDS",
                                "MDS/MPN with ringed sideroblasts and thrombocytosis (RS-T)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "as confirmed in the most recent local bone marrow biopsy report according to WHO criteria",
                    "criterion": "bone marrow biopsy confirmation",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "criteria",
                            "expected_value": "WHO criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Prior treatment with hypomethylating agent or other acute myeloid leukemia (AML)-like combination chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with hypomethylating agent",
                    "criterion": "prior treatment with hypomethylating agent",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... other acute myeloid leukemia (AML)-like combination chemotherapy",
                    "criterion": "prior treatment with AML-like combination chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "23. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days prior to Screening",
            "criterions": [
                {
                    "exact_snippets": "Participation in any other clinical protocol or investigational study",
                    "criterion": "participation in other clinical protocol or investigational study",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "that involves administration of experimental therapy and/or therapeutic devices",
                    "criterion": "administration of experimental therapy and/or therapeutic devices",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "within 30 days prior to Screening",
                    "criterion": "time since participation in other clinical protocol or investigational study",
                    "requirements": [
                        {
                            "requirement_type": "time since participation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. For Phase 1b: DIPSS score of 3 to 4 (intermediate 2 risk) or ≥5 (high-risk) primary MF, post PV MF, and/or post ET MF, as confirmed in the most recent local bone marrow biopsy report, according to WHO 2016 criteria.63",
            "criterions": [
                {
                    "exact_snippets": "DIPSS score of 3 to 4 (intermediate 2 risk) or ≥5 (high-risk)",
                    "criterion": "DIPSS score",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": ""
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "risk group",
                            "expected_value": "intermediate 2"
                        }
                    ]
                },
                {
                    "exact_snippets": "DIPSS score of ... ≥5 (high-risk)",
                    "criterion": "DIPSS score",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": ""
                            }
                        },
                        {
                            "requirement_type": "risk group",
                            "expected_value": "high-risk"
                        }
                    ]
                },
                {
                    "exact_snippets": "primary MF, post PV MF, and/or post ET MF",
                    "criterion": "myelofibrosis type",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "primary MF",
                                "post PV MF",
                                "post ET MF"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "as confirmed in the most recent local bone marrow biopsy report",
                    "criterion": "bone marrow biopsy report",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "according to WHO 2016 criteria",
                    "criterion": "WHO 2016 criteria",
                    "requirements": [
                        {
                            "requirement_type": "diagnostic standard",
                            "expected_value": "WHO 2016"
                        }
                    ]
                }
            ]
        },
        {
            "line": "TD low transfusion burden cohort: RBC transfusion dependence, defined as an RBC transfusion requirement of 1 to 2 PRBC units over the 84 days immediately prior to Screening",
            "criterions": [
                {
                    "exact_snippets": "RBC transfusion dependence, defined as an RBC transfusion requirement of 1 to 2 PRBC units over the 84 days immediately prior to Screening",
                    "criterion": "RBC transfusion dependence",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "PRBC units"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "PRBC units"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "over the 84 days immediately prior to Screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. JAK inhibitors require 12 weeks of stable dosing prior to Screening. For the TD cohort and nTD cohort, JAK inhibitors allowed include ruxolitinib and fedratinib. For the exploratory cohort, JAK inhibitors allowed include momelotinib and pacritinib (note: enrollment will commence with momelotinib only; pacritinib enrollment will be considered after initial safety and efficacy review).",
            "criterions": [
                {
                    "exact_snippets": "JAK inhibitors require 12 weeks of stable dosing prior to Screening",
                    "criterion": "JAK inhibitor dosing",
                    "requirements": [
                        {
                            "requirement_type": "stable dosing duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "For the TD cohort and nTD cohort, JAK inhibitors allowed include ruxolitinib and fedratinib",
                    "criterion": "JAK inhibitor type (TD and nTD cohorts)",
                    "requirements": [
                        {
                            "requirement_type": "allowed agents",
                            "expected_value": [
                                "ruxolitinib",
                                "fedratinib"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "For the exploratory cohort, JAK inhibitors allowed include momelotinib and pacritinib (note: enrollment will commence with momelotinib only; pacritinib enrollment will be considered after initial safety and efficacy review)",
                    "criterion": "JAK inhibitor type (exploratory cohort)",
                    "requirements": [
                        {
                            "requirement_type": "allowed agents",
                            "expected_value": [
                                "momelotinib",
                                "pacritinib"
                            ]
                        },
                        {
                            "requirement_type": "initial enrollment agent",
                            "expected_value": "momelotinib"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Medical history of ≤12 units of PRBC for MDS and anemia",
            "criterions": [
                {
                    "exact_snippets": "Medical history of ≤12 units of PRBC for MDS and anemia",
                    "criterion": "PRBC transfusion history",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "units"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Erythropoietin-stimulating agent",
            "criterions": [
                {
                    "exact_snippets": "Erythropoietin-stimulating agent",
                    "criterion": "erythropoietin-stimulating agent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Exclusion Criteria Exclusion Criteria for Participants with MF and Anemia",
            "criterions": [
                {
                    "exact_snippets": "Participants with MF and Anemia",
                    "criterion": "myelofibrosis (MF)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with MF and Anemia",
                    "criterion": "anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Inadequately controlled heart disease (New York Heart Association Classification 3 or 4) and/or known to have left ventricular ejection fraction <35%",
            "criterions": [
                {
                    "exact_snippets": "Inadequately controlled heart disease (New York Heart Association Classification 3 or 4)",
                    "criterion": "heart disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "inadequately controlled"
                        },
                        {
                            "requirement_type": "NYHA classification",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "known to have left ventricular ejection fraction <35%",
                    "criterion": "left ventricular ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 35,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2).",
            "criterions": [
                {
                    "exact_snippets": "Negative urine pregnancy test (females of childbearing potential) at Screening (Days 28 to 2)",
                    "criterion": "urine pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at Screening (Days 28 to 2)"
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "females of childbearing potential"
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. If male with female sexual partner(s) of childbearing potential, agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose:",
            "criterions": [
                {
                    "exact_snippets": "male with female sexual partner(s) of childbearing potential",
                    "criterion": "sexual partner's childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "partner sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "partner childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agrees to use one of the following acceptable methods of contraception during the study and for at least 8 weeks after the last study drug dose",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of contraception use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 8,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Medical History, Participants with MDS and Anemia",
            "criterions": [
                {
                    "exact_snippets": "Participants with MDS",
                    "criterion": "myelodysplastic syndrome (MDS)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with ... Anemia",
                    "criterion": "anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Peripheral blasts ≥5%",
            "criterions": [
                {
                    "exact_snippets": "Peripheral blasts ≥5%",
                    "criterion": "peripheral blasts",
                    "requirements": [
                        {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "24. Condition or concomitant medication that would confound the ability to interpret study data",
            "criterions": [
                {
                    "exact_snippets": "Condition ... that would confound the ability to interpret study data",
                    "criterion": "condition",
                    "requirements": [
                        {
                            "requirement_type": "potential to confound study data interpretation",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "concomitant medication that would confound the ability to interpret study data",
                    "criterion": "concomitant medication",
                    "requirements": [
                        {
                            "requirement_type": "potential to confound study data interpretation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Secondary MDS, ie, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation from other diseases",
            "criterions": [
                {
                    "exact_snippets": "Secondary MDS, ie, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation from other diseases",
                    "criterion": "secondary MDS",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": [
                                "chemical injury",
                                "treatment with chemotherapy",
                                "treatment with radiation from other diseases"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Systemic corticosteroids are permitted for non-hematological conditions if stable or decreasing dose for ≥28 days prior to Screening and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening.",
            "criterions": [
                {
                    "exact_snippets": "Systemic corticosteroids are permitted for non-hematological conditions",
                    "criterion": "systemic corticosteroid use for non-hematological conditions",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if stable or decreasing dose for ≥28 days prior to Screening",
                    "criterion": "systemic corticosteroid dose stability",
                    "requirements": [
                        {
                            "requirement_type": "dose stability",
                            "expected_value": "stable or decreasing"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening",
                    "criterion": "systemic corticosteroid dose",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg prednisone"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "=",
                                "value": 28,
                                "unit": "days immediately prior to Screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Serum ferritin ≥30 50 µg/L at Screening.",
            "criterions": [
                {
                    "exact_snippets": "Serum ferritin ≥30 50 µg/L at Screening",
                    "criterion": "serum ferritin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "µg/L"
                            }
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "at Screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. A history of anti-drug antibody formation",
            "criterions": [
                {
                    "exact_snippets": "A history of anti-drug antibody formation",
                    "criterion": "anti-drug antibody formation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. basal or squamous cell carcinoma",
            "criterions": [
                {
                    "exact_snippets": "basal or squamous cell carcinoma",
                    "criterion": "carcinoma type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "basal cell carcinoma",
                                "squamous cell carcinoma"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "23. Pregnant or lactating",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Platelet count ≥25,000/μL and <1,000,000/μL, and total WBC count <50,000/μL at Screening or otherwise approved by Sponsor",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥25,000/μL and <1,000,000/μL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 25000,
                                        "unit": "/μL"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 1000000,
                                        "unit": "/μL"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "total WBC count <50,000/μL",
                    "criterion": "total WBC count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50000,
                                "unit": "/μL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "TD high transfusion burden cohort: RBC transfusion dependence, defined as an RBC transfusion requirement of 3 to 12 PRBC units over the 84 days immediately prior to Screening",
            "criterions": [
                {
                    "exact_snippets": "RBC transfusion dependence, defined as an RBC transfusion requirement of 3 to 12 PRBC units over the 84 days immediately prior to Screening",
                    "criterion": "RBC transfusion requirement",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "PRBC units"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 12,
                                        "unit": "PRBC units"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "over the 84 days immediately prior to Screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "19. Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment) Treatment History, Participants with MDS and Anemia",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled fungal, bacterial, or viral infection (ongoing signs/symptoms related to the infection, without improvement despite appropriate treatment)",
                    "criterion": "infection status",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "fungal",
                                "bacterial",
                                "viral"
                            ]
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "ongoing signs/symptoms",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "improvement despite appropriate treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Direct bilirubin <2x ULN at Screening. Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis or Gilbert's syndrome, with approval from Sponsor.",
            "criterions": [
                {
                    "exact_snippets": "Direct bilirubin <2x ULN at Screening",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Higher levels are acceptable if these can be attributed by the Investigator to ineffective erythropoiesis or Gilbert's syndrome, with approval from Sponsor",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": ">= 2x ULN"
                        },
                        {
                            "requirement_type": "attribution",
                            "expected_value": [
                                "ineffective erythropoiesis",
                                "Gilbert's syndrome"
                            ]
                        },
                        {
                            "requirement_type": "investigator_approval",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "sponsor_approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review. Required for TD high participants only.",
            "criterions": [
                {
                    "exact_snippets": "Liver iron concentration by MRI <7 mg/g dry weight within 3 months of eligibility confirmation by central review",
                    "criterion": "liver iron concentration by MRI",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 7,
                                "unit": "mg/g dry weight"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 3 months of eligibility confirmation by central review"
                        }
                    ]
                },
                {
                    "exact_snippets": "Required for TD high participants only",
                    "criterion": "participant transfusion dependence status",
                    "requirements": [
                        {
                            "requirement_type": "group membership",
                            "expected_value": "TD high participants only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "26. Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days prior to Screening",
            "criterions": [
                {
                    "exact_snippets": "Participation in any other clinical protocol or investigational study",
                    "criterion": "participation in other clinical protocol or investigational study",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "that involves administration of experimental therapy and/or therapeutic devices",
                    "criterion": "administration of experimental therapy or therapeutic devices",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "within 30 days prior to Screening",
                    "criterion": "time since participation in other clinical protocol or investigational study",
                    "requirements": [
                        {
                            "requirement_type": "time since participation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Change in anticoagulant therapy regimen within 8 weeks prior to Screening Laboratory Exclusions, Medical History, Participants with MF and Anemia",
            "criterions": [
                {
                    "exact_snippets": "Change in anticoagulant therapy regimen within 8 weeks prior to Screening",
                    "criterion": "anticoagulant therapy regimen",
                    "requirements": [
                        {
                            "requirement_type": "change_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks prior to Screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "21. Change in anticoagulant therapy regimen within 8 weeks prior to Screening Laboratory Exclusions, Participants with MDS and Anemia",
            "criterions": [
                {
                    "exact_snippets": "Change in anticoagulant therapy regimen within 8 weeks prior to Screening",
                    "criterion": "anticoagulant therapy regimen",
                    "requirements": [
                        {
                            "requirement_type": "change_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks prior to Screening"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with MDS and Anemia",
                    "criterion": "myelodysplastic syndrome (MDS) and anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Hereditary hemochromatosis",
            "criterions": [
                {
                    "exact_snippets": "Hereditary hemochromatosis",
                    "criterion": "hereditary hemochromatosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Erythropoietin-stimulating agents",
            "criterions": [
                {
                    "exact_snippets": "Erythropoietin-stimulating agents",
                    "criterion": "erythropoietin-stimulating agents",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Washout of at least 28 days is required for prior anemia/neutropenia-directed therapies, including:",
            "criterions": [
                {
                    "exact_snippets": "Washout of at least 28 days is required for prior anemia/neutropenia-directed therapies",
                    "criterion": "washout period for prior anemia/neutropenia-directed therapies",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "25. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study",
            "criterions": [
                {
                    "exact_snippets": "Other medical or psychiatric condition ... that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study",
                    "criterion": "other medical or psychiatric condition",
                    "requirements": [
                        {
                            "requirement_type": "risk assessment",
                            "expected_value": "would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study, in the judgment of the Investigator or Sponsor"
                        }
                    ]
                },
                {
                    "exact_snippets": "laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study",
                    "criterion": "other laboratory finding",
                    "requirements": [
                        {
                            "requirement_type": "risk assessment",
                            "expected_value": "would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study, in the judgment of the Investigator or Sponsor"
                        }
                    ]
                }
            ]
        },
        {
            "line": "20. Iron chelation therapy in the 28 days prior to Screening",
            "criterions": [
                {
                    "exact_snippets": "Iron chelation therapy in the 28 days prior to Screening",
                    "criterion": "iron chelation therapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to Screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Systemic corticosteroids (except for participants on a stable or decreasing dose for ≥28 days prior to randomization for non-hematological conditions and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening) Screening can begin before the 28-day washout is completed, but the washout period must be completed prior to collection of Screening blood samples.",
            "criterions": [
                {
                    "exact_snippets": "Systemic corticosteroids (except for participants on a stable or decreasing dose for ≥28 days prior to randomization for non-hematological conditions and receiving an equivalent to ≤10 mg prednisone for the 28 days immediately prior to Screening)",
                    "criterion": "systemic corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception: dose stability or decrease for non-hematological conditions",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "exception: dose amount",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg prednisone"
                            }
                        },
                        {
                            "requirement_type": "exception: dose duration",
                            "expected_value": {
                                "operator": "=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "the washout period must be completed prior to collection of Screening blood samples",
                    "criterion": "systemic corticosteroid washout period",
                    "requirements": [
                        {
                            "requirement_type": "completion before screening blood collection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Major surgery within 8 weeks prior to Screening or incomplete recovery from any previous surgery",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 8 weeks prior to Screening",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to Screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "incomplete recovery from any previous surgery",
                    "criterion": "recovery from previous surgery",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": "incomplete"
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Stroke, deep vein thrombosis, or pulmonary or arterial embolism within 6 months prior to Screening",
            "criterions": [
                {
                    "exact_snippets": "Stroke ... within 6 months prior to Screening",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "deep vein thrombosis ... within 6 months prior to Screening",
                    "criterion": "deep vein thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "pulmonary or arterial embolism within 6 months prior to Screening",
                    "criterion": "pulmonary embolism",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "pulmonary or arterial embolism within 6 months prior to Screening",
                    "criterion": "arterial embolism",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Imetelstat",
            "criterions": [
                {
                    "exact_snippets": "Imetelstat",
                    "criterion": "Imetelstat",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Total splenectomy",
            "criterions": [
                {
                    "exact_snippets": "Total splenectomy",
                    "criterion": "total splenectomy",
                    "requirements": [
                        {
                            "requirement_type": "history/presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Symptomatic bleeding, unrelated to surgery, in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥2 g/dL or leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic bleeding, unrelated to surgery, in a critical area or organ",
                    "criterion": "symptomatic bleeding",
                    "requirements": [
                        {
                            "requirement_type": "relation to surgery",
                            "expected_value": "unrelated"
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "critical area or organ"
                        }
                    ]
                },
                {
                    "exact_snippets": "bleeding causing a decrease in Hgb of ≥2 g/dL",
                    "criterion": "bleeding-induced hemoglobin decrease",
                    "requirements": [
                        {
                            "requirement_type": "hemoglobin decrease",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "bleeding ... leading to transfusion of ≥2 units of RBCs in the 6 months prior to Screening",
                    "criterion": "bleeding-induced RBC transfusion",
                    "requirements": [
                        {
                            "requirement_type": "RBC transfusion units",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "units"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "6 months prior to Screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Androgens",
            "criterions": [
                {
                    "exact_snippets": "Androgens",
                    "criterion": "androgens",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Malignancy within the past 3 years, other than MDS or MDS/MPN without excess blasts. The following history or concurrent conditions are allowed:",
            "criterions": [
                {
                    "exact_snippets": "Malignancy within the past 3 years, other than MDS or MDS/MPN without excess blasts.",
                    "criterion": "malignancy (excluding MDS or MDS/MPN without excess blasts)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "22. Positive direct antiglobulin test in conjunction with a reactive RBC eluate at Screening Miscellaneous, Participants with MDS and Anemia",
            "criterions": [
                {
                    "exact_snippets": "Positive direct antiglobulin test",
                    "criterion": "direct antiglobulin test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "reactive RBC eluate at Screening",
                    "criterion": "RBC eluate",
                    "requirements": [
                        {
                            "requirement_type": "reactivity at Screening",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with MDS and Anemia",
                    "criterion": "myelodysplastic syndrome (MDS)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with MDS and Anemia",
                    "criterion": "anemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. histologic finding of prostate cancer (T1a or T1b using the TNM clinical staging system) A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement",
            "criterions": [
                {
                    "exact_snippets": "histologic finding of prostate cancer (T1a or T1b using the TNM clinical staging system)",
                    "criterion": "prostate cancer histology",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "TNM stage",
                            "expected_value": [
                                "T1a",
                                "T1b"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "A history of completed treatment (medical or surgical) of stage 1-2 cancers may be permitted with prior Sponsor agreement",
                    "criterion": "history of completed treatment of stage 1-2 cancers",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "completed"
                        },
                        {
                            "requirement_type": "cancer stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "stage"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "stage"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "sponsor agreement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Erythropoietin",
            "criterions": [
                {
                    "exact_snippets": "Erythropoietin",
                    "criterion": "erythropoietin",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Intrauterine device in place for at least 3 months (female partner)",
            "criterions": [
                {
                    "exact_snippets": "Intrauterine device in place",
                    "criterion": "intrauterine device",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for at least 3 months",
                    "criterion": "intrauterine device duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "(female partner)",
                    "criterion": "female partner",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "19. Positive direct antiglobulin test in conjunction with a reactive RBC eluate at Screening Miscellaneous, Medical History, Participants with MF and Anemia",
            "criterions": [
                {
                    "exact_snippets": "Positive direct antiglobulin test",
                    "criterion": "direct antiglobulin test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "reactive RBC eluate at Screening",
                    "criterion": "RBC eluate",
                    "requirements": [
                        {
                            "requirement_type": "reactivity at Screening",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Imetelstat",
            "criterions": [
                {
                    "exact_snippets": "Imetelstat",
                    "criterion": "Imetelstat",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "N/A"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Hydroxyurea, or, if taking any other treatment for MF, stable for at least 28 days prior to Screening.",
            "criterions": [
                {
                    "exact_snippets": "Hydroxyurea",
                    "criterion": "hydroxyurea treatment",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if taking any other treatment for MF, stable for at least 28 days prior to Screening",
                    "criterion": "other treatment for MF",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Age 18 years or older at the time of signing the ICF.",
            "criterions": [
                {
                    "exact_snippets": "Age 18 years or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Participants are eligible for the MDS exploratory cohort if all of the following criteria apply:",
            "criterions": [
                {
                    "exact_snippets": "Participants are eligible for the MDS exploratory cohort",
                    "criterion": "eligibility for MDS exploratory cohort",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "14. Hepatitis B or C, or human immunodeficiency virus (HIV) with detectable viral load",
            "criterions": [
                {
                    "exact_snippets": "Hepatitis B ... with detectable viral load",
                    "criterion": "Hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "viral load detectability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hepatitis C ... with detectable viral load",
                    "criterion": "Hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "viral load detectability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "human immunodeficiency virus (HIV) with detectable viral load",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "viral load detectability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Participants are eligible for the study if all of the following criteria apply:",
            "criterions": []
        },
        {
            "line": "4. Prior treatment with >1anemia-directed therapies including:",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with >1 anemia-directed therapies",
                    "criterion": "prior anemia-directed therapies",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapies",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Active hepatitis B or C, or HIV with detectable viral load",
            "criterions": [
                {
                    "exact_snippets": "Active hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Active hepatitis C",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HIV with detectable viral load",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "viral load detectability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "For Phase 2:",
            "criterions": []
        },
        {
            "line": "13. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3x upper limit of normal (ULN) at Screening.",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) <3x upper limit of normal (ULN) at Screening",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) <3x upper limit of normal (ULN) at Screening",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}